Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
McKesson
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson

Last Updated: May 16, 2022

Investigational Drug Information for Retosiban


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Retosiban?

Retosiban is an investigational drug.

There have been 8 clinical trials for Retosiban. The most recent clinical trial was a Phase 3 trial, which was initiated on February 29th 2016.

The most common disease conditions in clinical trials are Obstetric Labor, Premature, Premature Birth, and [disabled in preview]. The leading clinical trial sponsors are GlaxoSmithKline, PPD, and Tel-Aviv Sourasky Medical Center.

There are sixteen US patents protecting this investigational drug and one hundred and thirty-four international patents.

Recent Clinical Trials for Retosiban
TitleSponsorPhase
Tocolytic Therapy for Preterm Labor in Multiple GestationTel-Aviv Sourasky Medical CenterPhase 3
A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm LaborPPDPhase 3
A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm LaborGlaxoSmithKlinePhase 3

See all Retosiban clinical trials

Clinical Trial Summary for Retosiban

Top disease conditions for Retosiban
Top clinical trial sponsors for Retosiban

See all Retosiban clinical trials

US Patents for Retosiban

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Retosiban See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Retosiban See Plans and Pricing Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies Ferring B.V. (Hoofddorp, NL) See Plans and Pricing
Retosiban See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
Retosiban See Plans and Pricing Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof Merck Serono S.A. (Coinsins, CH) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Retosiban

Drugname Country Document Number Estimated Expiration Related US Patent
Retosiban Australia AU2017261372 2036-05-05 See Plans and Pricing
Retosiban Canada CA3023278 2036-05-05 See Plans and Pricing
Retosiban China CN107847398 2036-05-05 See Plans and Pricing
Retosiban European Patent Office EP3452003 2036-05-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
McKesson
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.